Novacyt (NCYT) Competitors GBX 38.29 -1.81 (-4.51%) As of 04/25/2025 11:08 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock NCYT vs. EKF, IUG, CREO, POLX, IHC, AVO, RUA, MHC, SUN, and BELLShould you be buying Novacyt stock or one of its competitors? The main competitors of Novacyt include EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), Creo Medical Group (CREO), Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), MyHealthChecked (MHC), Surgical Innovations Group (SUN), and Belluscura (BELL). These companies are all part of the "medical devices" industry. Novacyt vs. EKF Diagnostics Intelligent Ultrasound Group Creo Medical Group Polarean Imaging Inspiration Healthcare Group Advanced Oncotherapy RUA Life Sciences MyHealthChecked Surgical Innovations Group Belluscura EKF Diagnostics (LON:EKF) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends. Do institutionals and insiders have more ownership in EKF or NCYT? 70.3% of EKF Diagnostics shares are held by institutional investors. Comparatively, 0.1% of Novacyt shares are held by institutional investors. 5.2% of EKF Diagnostics shares are held by company insiders. Comparatively, 3.1% of Novacyt shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has better valuation and earnings, EKF or NCYT? EKF Diagnostics has higher revenue and earnings than Novacyt. Novacyt is trading at a lower price-to-earnings ratio than EKF Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEKF Diagnostics£49.91M1.87£4.68M£1.0719.54Novacyt£18.12M1.46-£36.80M-£54.44-0.70 Is EKF or NCYT more profitable? EKF Diagnostics has a net margin of 9.37% compared to Novacyt's net margin of -203.06%. EKF Diagnostics' return on equity of 7.03% beat Novacyt's return on equity.Company Net Margins Return on Equity Return on Assets EKF Diagnostics9.37% 7.03% 5.27% Novacyt -203.06%-47.73%-27.98% Does the MarketBeat Community prefer EKF or NCYT? EKF Diagnostics received 291 more outperform votes than Novacyt when rated by MarketBeat users. Likewise, 76.76% of users gave EKF Diagnostics an outperform vote while only 58.06% of users gave Novacyt an outperform vote. CompanyUnderperformOutperformEKF DiagnosticsOutperform Votes32776.76% Underperform Votes9923.24% NovacytOutperform Votes3658.06% Underperform Votes2641.94% Which has more risk and volatility, EKF or NCYT? EKF Diagnostics has a beta of 0.57, indicating that its stock price is 43% less volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, indicating that its stock price is 286% less volatile than the S&P 500. Does the media prefer EKF or NCYT? In the previous week, EKF Diagnostics' average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score. Company Overall Sentiment EKF Diagnostics Neutral Novacyt Neutral SummaryEKF Diagnostics beats Novacyt on 13 of the 13 factors compared between the two stocks. Get Novacyt News Delivered to You Automatically Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address NCYT vs. The Competition Export to ExcelMetricNovacytMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£26.46M£3.16B£5.47B£2.55BDividend YieldN/A2.45%5.43%4.80%P/E Ratio-0.7066.2822.39132.49Price / Sales1.46117.42391.41241,309.84Price / Cash0.5815.9938.1828.31Price / Book0.383.666.684.53Net Income-£36.80M£126.02M£3.22B£5.86B7 Day Performance-6.60%0.21%6.24%8.61%1 Month Performance-11.53%-7.84%-2.81%6.37%1 Year Performance-44.21%-14.94%16.47%103.30% Novacyt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCYTNovacytN/AGBX 38.29-4.5%N/A-44.5%£26.46M£18.12M-0.70120EKFEKF DiagnosticsN/AGBX 21.40-0.7%N/A-24.5%£95.12M£49.91M19.92356IUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165CREOCreo Medical GroupN/AGBX 9.59-0.4%N/A-73.3%£38.76M£33.87M-1.52279POLXPolarean ImagingN/AGBX 1.08+4.9%N/A-71.8%£15.78M£5.21M-0.2828Gap DownHigh Trading VolumeIHCInspiration Healthcare GroupN/AGBX 16.65+0.9%N/A-46.4%£14.42M£42.87M-1.14224AVOAdvanced OncotherapyN/AN/AN/AN/A£9.50MN/A-25.003,900Gap DownRUARUA Life SciencesN/AGBX 12.79+11.2%N/A+10.7%£7.94M£4.05M-2.9848MHCMyHealthCheckedN/AGBX 14.40+2.9%N/A+40.0%£7.49M£9.43M-7.1816SUNSurgical Innovations GroupN/AGBX 0.51-2.3%N/A+5.6%£4.79M£12.54M-21.1180News CoverageGap DownBELLBelluscuraN/AGBX 0.65+0.6%N/A-91.0%£1.65M£2.87M-0.0724 Related Companies and Tools Related Companies EKF Diagnostics Alternatives Intelligent Ultrasound Group Alternatives Creo Medical Group Alternatives Polarean Imaging Alternatives Inspiration Healthcare Group Alternatives Advanced Oncotherapy Alternatives RUA Life Sciences Alternatives MyHealthChecked Alternatives Surgical Innovations Group Alternatives Belluscura Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:NCYT) was last updated on 4/26/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.